Phase II trial of combination therapy with bevacizumab and S-1 in elderly patients with unresectable or recurrent colorectal cancer (BASIC).
Latest Information Update: 14 Sep 2015
Price :
$35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Bevacizumab
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms BASIC
- 28 Mar 2012 Planned end date changed from 1 Mar 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 20 Jun 2011 Planned end date changed from 1 Jun 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 28 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.